Significant rebound for the first time in 3 days. It was announced that Sanno Medical Center (Minato-ku, Tokyo) was added as a clinical trial implementation facility in a phase 3 clinical trial (placebo-controlled double-blind comparison test) in which recombinant human HGF (hepatocyte growth factor) protein preparations (KP-100LI) are administered to patients with vocal cord scars. With this addition, case integration will proceed at 6 domestic facilities, such as the Kyoto Prefectural University of Medicine Hospital, etc., and it is expected that case integration will accelerate.
クリングル---大幅に3日ぶり反発、声帯瘢痕対象のHGF第3相臨床試験で治験施設追加
Kringle --- major backlash for the first time in 3 days, clinical trial facility added in HGF phase 3 clinical trial targeting vocal cord scars
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.